Atlas Trials

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Clinical trial NCT07086469 · RECRUITING

Trial details

NCT number
NCT07086469
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
ToripalimabSurufatinibNeoadjuvant ImmunochemotherapyChemoradiotherapyEsophageal Squamous Cell Carcinoma
Start date
2025-07-20
Primary completion
2029-07-19
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.